Please assess the completion status of the following clinical trial:

Trial Title: Asacol Acute Diverticulitis(DIVA)Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* A clinical diagnosis of acute diverticulitis~* Female patients must be postmenopausal (at least 1 year without spontaneous menses) or surgically sterile or have a negative urine pregnancy test and practice acceptable contraception (e.g., abstinence; oral, intramuscular, or implanted hormonal contraception \[at least 3 months prior to enrollment\]; 2-barrier methods \[e.g., condom, diaphragm, or spermicide\]; intrauterine device or verbal report of partner with history of non-reversed vasectomy)~* Willing and able to participate in the study and provide a signed informed consent~Exclusion Criteria:~* Presence of diverticular complications (e.g., fistula, abscess, obstruction, stenosis);~* Active or recent history (within 6 months) of a peptic ulcer;~* Prior history of irritable bowel syndrome (IBS), as determined by the Investigator;~* History of major abdominal surgery (as determined by the Investigator);~* History of GI surgery within 3 months of diagnosis of acute diverticulitis;~* History of immunocompromising disease, human immunodeficiency virus (HIV) infection, or acquired immunodeficiency syndrome (AIDS);~* If female patient, active or recent history of endometriosis or dysmenorrhea;~* Received a dose of a product that contains, or is metabolized to, mesalamine by any route within 4 weeks before the screening visit;

- Gender: ALL
- Minimum Age: 35 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Days 1 thru Days 10 to 14 (Visit 2): daily antibiotic therapy, dietary advice, and 6 placebo tablets (matching mesalamine) once a day. Visit 2 thru Week 12 : 1 placebo capsule (matching probiotic) and 6 placebo tablets (matching mesalamine) daily.
- Mesalamine (Type: ACTIVE_COMPARATOR): Days 1 thru 10-14 (Visit 2): daily antibiotic therapy, dietary advice and 6 - 400 mg mesalamine tablets once a day. Visit 2 thru Week 12: 1 placebo capsule (matching probiotic) and 6 - 400 mg mesalamine tablets daily.
- Mesalamine & Probiotic (Type: ACTIVE_COMPARATOR): Days 1 thru 10-14 (Visit 2): daily antibiotic therapy, dietary advice and 6 - 400 mg mesalamine tablets once daily. Visit 2 thru Week 12: 1- Bifidobacterium infantis 35624 capsule and 6 - 400 mg mesalamine tablets daily

Based on this trial design, predict the completion outcome and termination type (if applicable).